SCHEMBL1018056

SCHEMBL1018056

CCCc1ccc(-c2ccc3c(c2)CCN(CC(=O)N2CCN(C4CCC4)CC2)C3)cc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.42
MLNR O43193 1/20 0.39
KDM4E B2RXH2 3/20 0.39
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
PKM P14618 2/20 0.38
GAA P10253 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PARP1 P09874 1/20 0.37
TACR1 P25103 1/20 0.37
HRH3 Q9Y5N1 4/20 0.37
KCNH2 Q12809 1/20 0.37
MEN1 O00255 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
ACHE P22303 2/20 0.36
MTNR1B P49286 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1014260 0.98 ALDH1A1 (0.45) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1016571 0.97 ALDH1A1 (0.46) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1016884 0.94 MLNR (0.46) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1018319 0.93 MLNR (0.48) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1017111 0.92 MAPT (0.42) ALDH1A1TSHRKMT2AKDM4EHTT
SCHEMBL1017918 0.92 MLNR (0.47) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1017983 0.90 ALDH1A1 (0.42) ALDH1A1TSHRKMT2AKDM4EHTT
SCHEMBL1017014 0.90 ALDH1A1 (0.41) ALDH1A1TSHRKMT2AMLNRKDM4E
SCHEMBL1016311 0.90 ALDH1A1 (0.43) ALDH1A1TSHRKMT2AKDM4EHTT
SCHEMBL1015085 0.88 ALDH1A1 (0.47) ALDH1A1TSHRKMT2AKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US claimed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ALDH1A1 1229/4885TSHR 314/4885KMT2A 566/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 1229/4885TSHR 314/4885KMT2A 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.